The official publication of Turkish Society of Clinical Biochemistry
Objective: Plasminogen activator inhibitor type I (PAI-1) an inhibitor of fibrinolysis and an important and independent cardiovascular risk factor, has been shown to be elevated in obesity. The aim of this study was to evaluate plasma PAI-1 levels in obese subjects and to...
Objective: Metabolic syndrome is a comorbidity of insulin resistance, impaired glucose tolerance, abdominal obesity, hypertension and dyslipidemia and associated with increased risk of cardiovascular disease. The secretion of adipocytokines such as leptin and adiponectin...
Fully Diamond OA with no APCs and no submission fees. Your research is freely available to readers worldwide from the day it publishes.
Double-blind peer review from an active editorial team returns a first decision in about 30 days, keeping your manuscript moving.
Backed by the Turkish Society of Clinical Biochemistry, JTCB welcomes submissions from researchers worldwide and reaches an international laboratory audience.
Method validation, analyzer comparisons, reference intervals, quality indicators, preanalytical studies, and instructive clinical case reports.
All manuscripts publish in English and follow ICMJE and COPE guidelines, with Crossref DOIs and TR Dizin indexing ensuring global discoverability.